<i>EGFR</i>-Mutant Non-Small-Cell Lung Cancer at Surgical Stages: What Is the Place for Tyrosine Kinase Inhibitors?

<i>EGFR</i>-Mutant Non-Small-Cell Lung Cancer at Surgical Stages: What Is the Place for Tyrosine Kinase Inhibitors?

The ADAURA trial has been significant for the perception of <i>EGFR</i> tyrosine kinase inhibitors (TKIs) as a tool for early stage non-small-cell lung cancer (NSCLC). It produced such great insight that the main TKI, Osimertinib, was rapidly integrated into international guidelines for...

Full description

Bibliographic Details
Main Authors: Xavier Cansouline, Béatrice Lipan, Damien Sizaret, Anne Tallet, Christophe Vandier, Delphine Carmier, Antoine Legras
Format: Article
Language:English
Published: MDPI AG 2022-04-01
Series:Cancers
Subjects:
<i>EGFR</i>
NSCLC
adjuvant
neoadjuvant
targeted therapy
resected lung cancer
Online Access:https://www.mdpi.com/2072-6694/14/9/2257

Internet

https://www.mdpi.com/2072-6694/14/9/2257

Similar Items